Vanguard Group Inc. Sells 64,339 Shares of Integra LifeSciences Holdings Corporation $IART

Key Points

• Vanguard Group Inc. reduced its stake in Integra LifeSciences Holdings Corporation by 0.8%, owning approximately 7.5 million shares, valued at about $165 million as of the latest SEC filing.
• Integra LifeSciences reported a quarterly revenue of $415.61 million and earnings per share (EPS) of $0.45, surpassing analysts' expectations of $0.43 EPS.
• Several analysts have downgraded Integra LifeSciences' stock price targets, with JPMorgan reducing it from $24 to $12, indicating a negative outlook.

Vanguard Group Inc. cut its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 0.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,516,628 shares of the life sciences company's stock after selling 64,339 shares during the quarter. Vanguard Group Inc. owned approximately 9.73% of Integra LifeSciences worth $165,291,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its position in Integra LifeSciences by 821.7% in the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after buying an additional 1,931 shares in the last quarter. CWM LLC grew its stake in shares of Integra LifeSciences by 413.8% during the first quarter. CWM LLC now owns 6,664 shares of the life sciences company's stock valued at $147,000 after purchasing an additional 5,367 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Integra LifeSciences during the first quarter valued at approximately $223,000. NorthRock Partners LLC bought a new stake in shares of Integra LifeSciences during the fourth quarter valued at approximately $251,000. Finally, LPL Financial LLC bought a new stake in shares of Integra LifeSciences during the fourth quarter valued at approximately $255,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have weighed in on IART. JMP Securities dropped their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. Wells Fargo & Company lowered their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and four have given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus target price of $18.63.

Integra LifeSciences Price Performance

Shares of NASDAQ IART traded down $0.60 during mid-day trading on Monday, hitting $14.26. 498,239 shares of the stock traded hands, compared to its average volume of 1,028,576. The company has a market cap of $1.11 billion, a PE ratio of -2.18, a price-to-earnings-growth ratio of 0.84 and a beta of 1.16. Integra LifeSciences Holdings Corporation has a twelve month low of $11.06 and a twelve month high of $27.13. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. The firm has a 50 day simple moving average of $12.77 and a two-hundred day simple moving average of $16.32.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. The business had revenue of $415.61 million for the quarter, compared to analyst estimates of $395.06 million. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.Integra LifeSciences's quarterly revenue was down .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 EPS. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. As a group, equities research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.